- Pfizer (PFE) reported third-quarter 2025 adjusted earnings per share of 87 cents, beating estimates. Revenues of $16.7 billion declined due to lower sales of COVID-19 products. International revenues rose, but U.S. revenues fell.
- In the Primary Care segment, Eliquis sales increased, but Prevnar family revenues declined. Comirnaty and Paxlovid sales were down, while Nurtec ODT/Vydura contributed positively.
- Pfizer’s Specialty Care segment saw growth in Vyndaqel family revenues but declines in Xeljanz and Enbrel sales. In the Oncology segment, Ibrance revenues decreased, while ADCs like Adcetris and Padcev showed mixed results.
- Pfizer reaffirmed its 2025 revenue guidance but raised its EPS outlook due to strong performance. The company projects total revenues between $61.0 billion and $64.0 billion and adjusted EPS between $3.00 and $3.15.
- Despite beating estimates, Pfizer’s stock dipped 1% in pre-market trading. The company is embroiled in a battle with Novo Nordisk over the acquisition of obesity drug developer Metsera. Pfizer also signed a drug pricing agreement with the Trump administration.
- Pfizer’s Zacks Rank is currently #4 (Sell). The company’s outlook for 2025 remains positive, with the potential for growth in revenues and earnings. The industry is closely watching Pfizer’s strategic moves in the pharmaceutical sector.
Read more at Nasdaq: Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools